[PDF][PDF] This is a repository copy of Mapping from visual acuity to EQ-5D, EQ-5D with vision bolt-on, and VFQ-UI in patients with macular edema in the LEAVO trial.
BM Pennington, M Hernández-Alava, P Hykin - core.ac.uk
Objectives: Mappings to convert clinical measures to preference-based measures of health
such as the EQ-5D-3L are sometimes required in cost-utility analyses. We developed …
such as the EQ-5D-3L are sometimes required in cost-utility analyses. We developed …
[HTML][HTML] Mapping from visual acuity to EQ-5D, EQ-5D with vision Bolt-On, and VFQ-UI in patients with macular edema in the LEAVO trial
BM Pennington, M Hernández-Alava, P Hykin… - Value in Health, 2020 - Elsevier
Objectives Mappings to convert clinical measures to preference-based measures of health
such as the EQ-5D-3L are sometimes required in cost-utility analyses. We developed …
such as the EQ-5D-3L are sometimes required in cost-utility analyses. We developed …
Economic Evaluation of Treatment of Macular Edema Due to Central or Hemiretinal Vein Occlusion in the SCORE 2 Trial
S Kymes, NL Oden… - … & Visual Science, 2021 - iovs.arvojournals.org
Purpose: The main outcome results of the SCORE2 trial demonstrated that, among patients
with macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO) …
with macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO) …
Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study
B Pennington, A Alshreef, L Flight, A Metry, E Poku… - …, 2021 - Springer
Background We aimed to assess the cost effectiveness of intravitreal ranibizumab
(Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular …
(Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular …
Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study.
Y Yang - 2021 - rwt.dspace-express.com
Background: We aimed to assess the cost effectiveness of intravitreal ranibizumab
(Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular …
(Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular …
Mapping the 25-item national eye institute visual functioning questionnaire (NEI VFQ-25) to EQ-5D utility scores
S Kay, A Ferreira - Ophthalmic epidemiology, 2014 - Taylor & Francis
Purpose: To develop a mapping algorithm for the estimation of EQ-5D-based utility scores
from observed 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) …
from observed 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) …
PSS20 cost-utility analysis of treatments for macular edema secondary to retinal vein occlusion
S Duff, J Gricar, S Kymes, I Tran, A Turpcu… - Value in …, 2012 - valueinhealthjournal.com
Objectives Quantify the cost effectiveness of treatments for macular edema (ME) secondary
to branch or central retinal vein occlusion (BRVO, CRVO) from US payer/societal …
to branch or central retinal vein occlusion (BRVO, CRVO) from US payer/societal …
Intravitreal bevacizumab cost saving for macular oedema in the UK
B Pennington - PharmacoEconomics & Outcomes News, 2021 - Springer
Wider use of intravitreal bevacizumab [Avastin; Roche] appears to be cost saving in the UK
compared with aflibercept [Eylea; Bayer Pharma] and ranibizumab [Lucentis; Novartis] for …
compared with aflibercept [Eylea; Bayer Pharma] and ranibizumab [Lucentis; Novartis] for …
PSS30 Assessment of Utility Loss From Diabetic Macular Edema Based on Restore Trial
MS Knudsen, S Thomas, M Gallagher… - Value in …, 2011 - valueinhealthjournal.com
Objectives Evidence is limited on the extent to which health state utility decrements differ
between changes in the better-seeing and worse-seeing eyes following treatment. This …
between changes in the better-seeing and worse-seeing eyes following treatment. This …
[HTML][HTML] PIN156 INTRAVITREAL THERAPY WITH RANIBIZUMAB VS AFLIBERCEPT VS BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL …
L Flight, A Alshreef, PG Hykin… - Value in …, 2019 - valueinhealthjournal.com
Objectives We aimed to evaluate the cost-effectiveness of aflibercept and bevacizumab
compared to ranibizumab for the treatment of macular oedema (MO) secondary to central …
compared to ranibizumab for the treatment of macular oedema (MO) secondary to central …